�Algeta ASA (OSE: ALGETA), the Norwegian cancer therapeutics company, announced that the primary objective of its BC1-03 Phase II bother
palliation survey was met. The study showed that even single doses of
Alpharadin in patients with painful bone metastases could produce
increasing clinical benefit with increasing dose. Pain palliation is an
important quality of life benefit in metastatic cancer patients. The tribulation
also confirmed Alpharadin's benign side-effect visibility and, importantly for
a drug in this clinical setting, no significant os marrow toxicity was
observed.
In manpower with HRPC life anticipation can be as short as 18 months, and it
is estimated that 100,000 men in the EU and USA die from the disease each
year. In 85% of these men the tumor will have spread into the bones. These
metastases ar a pregnant problem as they bathroom cause intractable and
debilitating pain as well as contributing to a farther reduction in life
expectancy.
The BC1-03 study was a double blind randomised pain control study
comparing the palliative personal effects of four-spot different single dose levels of
Alpharadin in patients with boney metastatic HRPC. The do drugs was given by
i.v. shot mainly on an outpatient basis. The palliative efficaciousness of
Alpharadin was deliberate using an assessment of bone pain as comfortably as the
patient's consumption of analgesia. The primary study objective was to
investigate whether there was a dose-response relationship with respect to
pain palliation in this patient group. The study has shown the good
palliative effect of a single dosage of Alpharadin and that there is a net
dose-response effect, with higher doses providing better pain in the ass relief.
The study likewise showed a dose-dependent simplification in os alkaline
phosphatase (ALP) ranging from no effect in the lowest dose mathematical group to a
marked reduction in the higher dot groups. ALP is a severity marker of
gaunt metastatic disease and of prognostic importance.
The study has also further confirmed the safe of Alpharadin and shown
its benign side-effect profile. In fact, the higher the elvis of Alpharadin
that patients received, the fewer inauspicious events were experienced. This
reproduces the safety profile of the earlier BC1-02 Phase II study where
the Alpharadin group experienced fewer inauspicious effects than the placebo
comparator group. Importantly for a do drugs in this clinical setting no
significant bone marrow toxicity was observed in patients receiving
Alpharadin.
The full results of the BC1-03 study will be submitted for publication
in a peer-reviewed journal.
The principal research worker of the study Professor Sten Nilsson at the
Karolinska Hospital in Stockholm said: "These results display the
good impact of Alpharadin in terms of pain palliation are important,
as improved quality of life, aboard increased survival, are the two key fruit
goals of anti-cancer therapy of patients with pinched metastases."
Commenting on today's further positive news with Alpharadin, Algeta's
President and CEO, Dr. Thomas Ramdahl, said: "These results build on the
positive Phase II clinical data package that we have already assembled with
Alpharadin, the highlight of which was the substantial survival benefits
that we have already reported in patients with HRPC.
Based on our clinical trials to-date I am identical confident that
Alpharadin has the potency to become an crucial new therapy for
patients with prostate cancer. This view has been reinforced by the
enthusiastic and positive response we have received from key judgment
leaders around the humans to our unique coming to treating HRPC."
Algeta has lately started enrolling patients for the polar Phase
III ALSYMPCA (ALpharadin in SYMptomatic Prostate CAncer) study. This
international written report will valuate Algeta's targeted therapeutic Alpharadin
in advanced, hormone-refractory prostate gland cancer (HRPC) that has
metastasized to the skeleton. Approximately 750 patients ar expected to be
enrolled at more than cxxv medical centers in Europe, Asia, South America
and Canada. The Coordinating Investigator for the study is Dr. Christopher
Parker, a leading clinical oncologist and specialist in prostate cancer the Crab,
based at the Institute of Cancer Research and the Royal Marsden Hospital in
the UK.
About Algeta
Algeta ASA is a Norwegian genus Cancer therapeutics company built on
world-leading, proprietary technology. Algeta is developing new, targeted
cancer therapeutics that harness the alone characteristics of alpha
subatomic particle emitters and are virile, well-tolerated and convenient to use.
Algeta's lead product candidate, Alpharadin, has commenced an
international phase III clinical trial in hormone-refractory prostate
cancer (ALSYMPCA) based on positive phase II results. Alpharadin is a novel
bone-seeking therapeutic based on the alpha particle emitter radium-223 and
may target wasted metastases from multiple genus Cancer types, as well as
primary ivory cancers.
Algeta is besides developing other technologies for delivering alpha
emitters. These include microparticles, liposomes, and methods to enhance
the potency of therapeutic antibodies and other tumor-targeting molecules
by linking them to the alpha particle
Thursday, 4 September 2008
Monday, 25 August 2008
Clinical News From Annals Of Internal Medicine
div
Latest News For Bones / Orthopaedics
Research Indicates No Justification For Denying Obese Patients Knee Replacements
21 Aug 2008
Enobia Pharma Initiates Clinical Testing Of Enzyme Replacement Therapy To Treat Hypophosphatasia
21 Aug 2008
Predicting Injury Of Military Personnel And Athletes
21 Aug 2008
View more news...
Latest Videos for Bones
Osteoporosis and Psychology
Understanding the psychological challenges of osteoporosis - and knowing how to cope with them - ar important goals for all women with this disease. In this webcast, the emotional issues facing women with osteoporosis...
Living with Osteoporosis
No picture of osteoporosis is complete without an understanding of the personal impact this disease can have. And no one can express this impact better than someone who is living with the disease. Join us as we talk to Cecilia Johnson about the physical and emotional challenges of her 15-year...
View more videos...
Most Popular Categories
More info
Latest News For Bones / Orthopaedics
Research Indicates No Justification For Denying Obese Patients Knee Replacements
21 Aug 2008
Enobia Pharma Initiates Clinical Testing Of Enzyme Replacement Therapy To Treat Hypophosphatasia
21 Aug 2008
Predicting Injury Of Military Personnel And Athletes
21 Aug 2008
View more news...
Latest Videos for Bones
Osteoporosis and Psychology
Understanding the psychological challenges of osteoporosis - and knowing how to cope with them - ar important goals for all women with this disease. In this webcast, the emotional issues facing women with osteoporosis...
Living with Osteoporosis
No picture of osteoporosis is complete without an understanding of the personal impact this disease can have. And no one can express this impact better than someone who is living with the disease. Join us as we talk to Cecilia Johnson about the physical and emotional challenges of her 15-year...
View more videos...
Most Popular Categories
cancer �
cardiovascular �
dermatology �
hiv �
nutrition �
diabetes �
obesity �
pediatrics �
psychology �
neurology �
alcohol �
urology �
breast cancer �
women's health �
infectious diseases �
respiratory �
sexual health �
gastrointestinal �
pain �
pregnancy �
bones �
medical devices �
medicare �
depression �
prostate �
smoking �
alzheimer's �
allergy �
sleep �
biology �
genetics �
eye health �
sports medicine �
hypertension �
abortion �
health insurance �
autism �
stem cell research �
adhd �
liver disease �
multiple sclerosis �
arthritis �
pharma industry �
seniors �
dentistry �
it �
nursing �
blood �
fertility �
More info
Thursday, 7 August 2008
Meg Ryan - Crowe Romance Rocked Ryans World
MEG RYAN was so upset by the way America turned on her during her 2000 romance with PROOF OF LIFE co-star RUSSELL CROWE she needed to take a break from Hollywood to recover.
The actress had long been considered America's lulu until the break-up of her
Friday, 27 June 2008
Sunday, 22 June 2008
Shins set to release album on Mercer's label
Indie band's first three albums were on Sub Pop
NEW YORK -- The Shins are likely to self-release their fourth studio album through frontman James Mercer's Aural Apothecary label. The beloved indie rock group's first three albums were released by Sub Pop.
"The deal will be more of a (pressing and distribution) deal than a traditional record deal," Shins manager Ian Montone said. "That partner could very well remain Sub Pop, who have done a remarkable job with the band and have a great staff of people who really love music. It could be a digital partner with respect to other rights. All of this is being determined. The first goal is to make the record and see where that takes us."
The Shins are seeking a deal that would allow them to own their masters, "and, in addition to the marketing tools we have at our own disposal, team up with a label partner that will assist with additional marketing, radio, and various costs," Montone reported.
For a band like the Shins, who have sold 1.58 million albums in the United States since 2001, according to Nielsen SoundScan, such a deal makes sense because "it allows them to have the best of all possible worlds -- control and ownership, as well as the ability to still partner with a label and be able to take advantage of that traditional infrastructure," according to Montone.
The band's most recent album, 2007's "Wincing the Night Away," debuted at a career-best No. 2 on the Billboard 200 and has sold more than 538,000 copies.
NEW YORK -- The Shins are likely to self-release their fourth studio album through frontman James Mercer's Aural Apothecary label. The beloved indie rock group's first three albums were released by Sub Pop.
"The deal will be more of a (pressing and distribution) deal than a traditional record deal," Shins manager Ian Montone said. "That partner could very well remain Sub Pop, who have done a remarkable job with the band and have a great staff of people who really love music. It could be a digital partner with respect to other rights. All of this is being determined. The first goal is to make the record and see where that takes us."
The Shins are seeking a deal that would allow them to own their masters, "and, in addition to the marketing tools we have at our own disposal, team up with a label partner that will assist with additional marketing, radio, and various costs," Montone reported.
For a band like the Shins, who have sold 1.58 million albums in the United States since 2001, according to Nielsen SoundScan, such a deal makes sense because "it allows them to have the best of all possible worlds -- control and ownership, as well as the ability to still partner with a label and be able to take advantage of that traditional infrastructure," according to Montone.
The band's most recent album, 2007's "Wincing the Night Away," debuted at a career-best No. 2 on the Billboard 200 and has sold more than 538,000 copies.
Sunday, 15 June 2008
Hbo - Former Critic Frank Rich To Help Develop Shows For Hbo
New York Times
Op-Ed columnist Frank Rich is becoming a "creative consultant" to HBO to participate
in the development of new programs. Rich has been a film and TV critic for Time
and a theater critic for the New York Times from 1980-1994. Rich told the
Times today (Thursday) that his role at HBO will be "to bring ideas, to vet
ideas, everything from comedies to documentaries to docudramas."
22/05/2008
See Also
Monday, 2 June 2008
Ali Wilson And DMF
Artist: Ali Wilson And DMF
Genre(s):
Trance
Discography:
Emanation
Year: 2007
Tracks: 1
Jennifer Aniston is a “clingy” girlfriend
Subscribe to:
Posts (Atom)